| Literature DB >> 32197549 |
Ahmed Zayed1,2, Roland Ulber1.
Abstract
Fucoidans are multifunctional marine macromolecules that are subjected to numerous and various downstream processes during their production. These processes were considered the most important abiotic factors affecting fucoidan chemical skeletons, quality, physicochemical properties, biological properties and industrial applications. Since a universal protocol for fucoidans production has not been established yet, all the currently used processes were presented and justified. The current article complements our previous articles in the fucoidans field, provides an updated overview regarding the different downstream processes, including pre-treatment, extraction, purification and enzymatic modification processes, and shows the recent non-traditional applications of fucoidans in relation to their characters.Entities:
Keywords: bioactivities; brown algae; extraction; fucoidans; production
Mesh:
Substances:
Year: 2020 PMID: 32197549 PMCID: PMC7142712 DOI: 10.3390/md18030170
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Global distribution of the major brown seaweeds’ species. They dominate tropical to temperate marine forests and intertidal regions.
Figure 2Required downstream processes including steps in each process for fucoidans production.
Figure 3Overview of optimized pre-treatment steps of the dried algae biomass before fucoidans extraction. All steps were performed at 25 °C overnight and the ratio between dried algal biomass to solvent was 1:10, except for the acetone step, which was 1:20 (modified after [98,102]).
Some selected recent therapeutic, diagnostic and pharmaceutical applications of fucoidans including the biogenic sources.
| Application | Biogenic Source | Quality Grade/Purification Method | Structural Features | Involved Mechanism | Ref. |
|---|---|---|---|---|---|
|
| |||||
| Anti-viral | * | Inhibition of the viral neuraminidase (NA) | [ | ||
| Anti-metabolic syndrome | Dialysis of crude alginate-free fucoidans | Alternating α(1→3)/α(1→4)linked fucose, | Regulation of jnk, akt, and ampk signaling | [ | |
| Anti-leishmaniasis | Commercial product purchased from Sigma-Aldrich® | Polymer of α-(1→3) linked fucose | Activation of the mitogen-activated protein kinase (MAPK)/NF-κB pathway against | [ | |
| Enhancement of dendritic cells maturation, production of | [ | ||||
| Immunostimulant | A fraction of DEAE Sepharose Fast Flow column | Highly branched polymer | Stimulation of RAW264.7 murine macrophage and NK cells | [ | |
| Anti-metastasis | DEAE-cellulose, and Sephadex G-100 column chromatography (purity>90%) | Mw: of 10.4356 × 104 g/mol | - Suppression of Hca-F cell growth, adhesion, invasion, and metastasis capabilities, | [ | |
| Gastrointestinal tract protective | Purity ≥ 95% (Commercial product purchased from Sigma-Aldrich®) | Protection against H2O2-induced damage via activation of the NRF2 signaling pathway | [ | ||
| Anti-malaria | - Partial purification by cetylpyridinum chloride | Sugar monomers, and uronic acid, | In-vitro and in-vivo inhibition of erythrocytes invasion by | [ | |
| Renal protective | LMWF | Inhibition of overexpression of pro-inflammatory and pro-fibrotic factors, oxidative stress and apoptosis | [ | ||
| Cardio-, hepatic- and renal protective | Commercial product purchased from Absunutrix Lyfetrition® | Reduction of oxidative stress, pro-inflammatory effects and injuries to the cardiac, hepatic, and renal tissues | [ | ||
| Inhibition of tumor angiogenesis | Hydrolyzed crude extract | LMWF; | Suppression of HIF-1/VEGF-regulated signaling pathway | [ | |
| Pro-angiogenic | Fractionated with dialysis commercial crude fucoidan (ASPHY) | LMWF | Increase of the vascular network formation regulated via Erk1/2 and PI3K/AKT cell signaling pathways | [ | |
| Alleviation of diabetic complications | Crude extract | Mw: 205.89x103 g/mol, | - Suppression of oxidative stress | [ | |
|
| |||||
| Imaging of cardiovascular diseases | An oxidative-reductive degraded crude extract (purchased from Algues and Mer, Ascophyscient®) | GMP-grade LMWF (7.1x103 g/mol) | Synthesis of technetium-99m-fucoidan radiotracer for detection of P-selectin | [ | |
| Commercial product from Algues and Mer | Synthesis of polycyanoacrylate-fucoidan microcapsules (Fuco-MCs) for detection of P-selectin | [ | |||
|
| |||||
| Anti-Photoaging | Enzymatic degradation of a commercial HMWF | LMWF (Mw: 8 × 103 g/mol) | Anti-oxidant, anti-apoptotic, and MMP-9-inhibiting effects | [ | |
| Skin brightening and age spot reduction | Crude extracts purchased from Marinova® Pty Ltd. | 58.6% fucoidans, | Increase of Sirtuin 1 ( | [ | |
| Skin immunity, soothing and protection | 89.6% fucoidans, | ||||
| Reconstruction of skin | Commercial product from Sigma-Aldrich® | Increase of proliferating cell nuclear antigen (PCNA) p63 and α6-integrin expression | [ | ||
|
| |||||
| As vehicle for drug delivery | Commercial product purchased from Sigma-Aldrich® | Mw: 57.26 ×103 g/mol | - Chitosan-fucoidans-based nanoparticles for delivery of anti-cancers (e.g., curcumin-loaded NPs) | [ | |
| Piperlongumine (PL)-loaded chitosan-fucoidan nanoparticles (PL-CS-F NPs) | [ | ||||
| Synthesis of fucoidan/trimethylchitosan nanoparticles (FUC-TMC-NPs) as adjuvant in anthrax vaccine adsorbed | [ | ||||
| Green synthesis of silver nanoparticles | Synthesis of chitosan-fucoidan complex-coated AgNPs | [ | |||
*: Not specified.
Source of fucoidans as a substrate and mode of action of some fucoidanases.
| Biogenic Source of Fucoidans | Fucoidanase Source | Mode of Action | Ref. |
|---|---|---|---|
|
| Endo | [ | |
| Endo | [ | ||
|
| Endo | [ | |
|
| Endo | [ | |
|
| Endo | [ | |
| Endo | [ | ||
|
|
| Endo | [ |
|
| Endo | [ | |
|
| Endo | [ | |
|
| Endo | [ | |
|
|
| Endo | [ |
|
|
| Exo | [ |
|
| Endo | [ |
* n.d.: not determined.